Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy
Zuo S, Sun L, Wang Y, Chen B, Wang J, Ge X, Lu Y, Yang N, Shen P. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy. Cell Death & Disease 2021, 12: 208. PMID: 33627636, PMCID: PMC7904926, DOI: 10.1038/s41419-021-03499-w.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzoatesCell LineageCoculture TechniquesGene Expression Regulation, LeukemicHumansHydrazinesJanus KinasesK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMice, NudeMitogen-Activated Protein KinasesPyrazolesReceptors, ThrombopoietinSignal TransductionSTAT Transcription FactorsThrombopoiesisUmbilical CordXenograft Model Antitumor AssaysConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsProgression of CMLCML cellsUC-MSCsDifferentiation therapyCurrent tyrosine kinase inhibitorsTherapeutic potentialMesenchymal stem cell treatmentAcute promyelocytic leukemia (APL) treatmentImmature white blood cellsSevere adverse effectsWhite blood cellsTrans retinoic acidStem cell treatmentStem/progenitor cellsComplete remissionTreatment regimenTumor burdenCML patientsCure rateMAPK signaling pathwaysPeripheral bloodHematopoietic stem/progenitor cellsMyeloid leukemia